Company / PP&E (Net)
Akebia Therapeutics, Inc. PP&E (Net) History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$1.2M
FY2025
5-year range
$1.2M / $6.8M
FY2021-FY2025
Trend
-44.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has declined for 6 consecutive years, from $10M in FY2019 to $1M in FY2025.
Based on SEC 10-K filings.
$1M in FY2025 with a 10-year CAGR of +8.5%.
Declined from $4M to $1M over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -38.3%
- 5-Year CAGR
- -32.3%
- 10-Year CAGR
- +8.5%
Key checks
Key Insights
- Akebia Therapeutics, Inc.'s pp&e (net) has declined for 6 consecutive years.
- 5-year CAGR of -32.3%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 44.5% year-over-year.
- Peak pp&e (net) was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score -2.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.2M | -44.5% |
| FY2024 | $2.2M | -39.4% |
| FY2023 | $3.6M | -30.4% |
| FY2022 | $5.2M | -22.8% |
| FY2021 | $6.8M | -21.7% |
| FY2020 | $8.6M | -16.9% |
| FY2019 | $10.4M | +29.4% |
| FY2018 | $8.0M | +1385.7% |
| FY2015 | $540.0K | +157.2% |
| FY2014 | $209.9K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026